http://orcid.org/0000-0002-0627-5297
References
- Isaacson PG, Chott A, Ott G, et al. Enteropathy-associated T-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of the haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. p. 89–291.
- Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi: 10.1182/blood-2016-01-643569
- Chan JK, Chan AC, Cheuk W, et al. Type II enteropathy-associated T-cell lymphoma: a distinct aggressive lymphoma with frequent γδ T-cell receptor expression. Am J Surg Pathol. 2011;35(10):1557–1569. doi: 10.1097/PAS.0b013e318222dfcd
- Tse E, Gill H, Loong F, et al. Type II enteropathy-associated T-cell lymphoma: a multicenter analysis from the Asia lymphoma study group. Am J Hematol. 2012;87(7):663–668. doi: 10.1002/ajh.23213
- Tan SY, Chuang SS, Tang T, et al. Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8αα phenotype. Leukemia. 2013;27(8):1688–1696. doi: 10.1038/leu.2013.41
- Tan SY, Ooi AS, Ang MK, et al. Nuclear expression of MATK is a novel marker of type II enteropathy-associated T-cell lymphoma. Leukemia. 2011;25(3):555–557. doi: 10.1038/leu.2010.295
- Swerdlow SH, Jaffe ES, Brousset P, et al. International lymphoma study group. Cytotoxic T-cell and NK-cell lymphomas: current questions and controversies. Am J Surg Pathol. 2014;38(10):e60–e71. doi: 10.1097/PAS.0000000000000295
- Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32(27):3048–3058. doi: 10.1200/JCO.2013.53.5229
- Hoffmann M, Vogelsang H, Kletter K, et al. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma. Gut. 2003;52(3):347–351. doi: 10.1136/gut.52.3.347
- Hadithi M, Mallant M, Oudejans J, et al. 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. J Nucl Med. 2006;47(10):1622–1627.
- Casulo C, Schöder H, Feeney J, et al. 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma. Leuk Lymphoma. 2013;54(10):2163–2167. doi: 10.3109/10428194.2013.767901
- Khong PL, Huang B, Lee EY, et al. Midtreatment 18F-FDG PET/CT scan for early response assessment of smile therapy in natural killer/T-cell lymphoma: a prospective study from a single center. J Nucl Med. 2014;55(6):911–916. doi: 10.2967/jnumed.113.131946
- Chan WK, Au WY, Wong CY, et al. Metabolic activity measured by F-18 FDG PET in natural killer-cell lymphoma compared to aggressive B- and T-cell lymphomas. Clin Nucl Med. 2010;35(8):571–575. doi: 10.1097/RLU.0b013e3181e4dcbf
- Mian M, Wasle I, Gritsch S, et al. B cell lymphoma with lung involvement: what is it about? Acta Haematol. 2015;133(2):221–225. doi: 10.1159/000365778
- Villa D, Connors JM, Shenkier TN, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010;21(5):1046–1052. doi: 10.1093/annonc/mdp432